CARTT therapy

Extracted Attributes

• Full Name

  Chimeric Antigen Receptor T-cell therapy

• Administration

  Single intravenous infusion

• Approved Products

  Kymriah, Tecartus, Yescarta, Breyanzi, Abecma, Carviykti

• Common Side Effects

  Cytokine release syndrome (CRS), Neurologic toxicities

• Mechanism of Action

  Genetic modification of T cells to target cancer-specific antigens

• Therapeutic Category

  Immunotherapy / Cell and Gene Therapy

• FDA-Approved Indications

  Acute lymphoblastic leukemia, Mantle cell lymphoma, Multiple myeloma, B-cell lymphomas

Timeline

• A study led by Dr. Connor Johnson at Massachusetts General Hospital highlights significant quality of life improvements for patients receiving CAR-T products. (Source: Web Search Results)

  2023-12-00

• FDA Commissioner Marty Makary discusses CARTT therapy as a promising technology during the JP Morgan Healthcare Conference in San Francisco. (Source: Document 065d2e96-4d40-49bd-8511-d8d35f8b01f4)

  2025-01-00

ICES

ICES (formerly known as the Institute for Clinical Evaluative Sciences) is an independent, non-profit corporation that applies the study of health informatics for health services research and population-wide health outcomes research in Ontario, Canada, using data collected through the routine administration of Ontario's system of publicly funded health care. ICES scientists have secure access to Ontario's health administrative data. ICES research teams produce peer-reviewed scientific journal articles, as well as reports and atlases to assist health care providers, government planners and policy makers in improving population health through the advancement of evidence-based practice and health policy. ICES was established in 1992 and is governed by a board of directors. ICES receives core funding from the Ontario Ministry of Health and Long-Term Care (MOHLTC). In addition, ICES faculty and staff receive peer-reviewed grants from federal funding agencies such as the Canadian Institutes of Health Research, and project-specific funds from provincial and national organizations. ICES' central location is on the campus of Sunnybrook Health Sciences Centre in Toronto, with satellite locations in Kingston, Ontario, London, Ontario, Hamilton, Ontario and Sudbury, Ontario.

Web Search Results

• A Promising Outlook: CAR T Cells Improve Patient Quality of Life

  CAR-T therapies are developed by harvesting a patient’s own T cells (the immune system’s primary cancer-killing cells), engineering them to target proteins specific to the surface of cancer cells, and reintroducing these modified T cells back into the patient’s immune system to kill the cancer cells. [...] “CAR-T has revolutionized the treatment of patients with relapsed and refractory blood cancers. But it remains a unique treatment with unique toxicities, including cytokine release syndrome, which is an inflammatory flu-like ailment, as well as neurologic toxicities. And these complications can take a toll on patients,” said Connor Johnson, MD, an oncologist at Massachusetts General Hospital and lead study author. “Given the relatively new development of CAR-T therapy, there are a limited set of studies that have examined patient reported outcomes in those receiving these treatments.” [...] Dr. Johnson explains that it is important to recognize the burden CAR-T therapy brings to some patients to maximize the effectiveness of these therapies and improve care for all individuals living with hematologic malignancies. “Here we show significant improvements in quality of life among patients with an array of blood cancer diagnoses, receiving a variety of CAR-T products,” said Dr. Johnson. “However, we also identify a distinct subset of patients who have persistent physical and psychological symptom burden, even at the six-month post CAR-T time point. And I hope that these findings lead to additional interventions with a goal of improving the overall quality of life trajectory of all patients.”

• Advantages of CAR-T Cell Therapy | Rutgers Cancer Institute

  One of the major advantages of CAR T-cell therapy is the short treatment time needed – administered with a single infusion that may require at the most, two weeks of inpatient care, and then it’s done. Because aggressive chemotherapy is not used, most patients have a much more rapid recovery than after stem cell transplants in which aggressive chemotherapy is used. At some point in the future, CAR T-cell therapy may even replace most types of transplants but at the current time, CAR T-cell therapy is approved for the treatment of patients in whom transplant is not likely to be curative or in patients who relapse after transplant. [...] CAR T-cell therapy is also a “living drug”, and its benefits can last for many years. Since the cells can persist in the body long-term, they may recognize and attack cancer cells if and when there’s a relapse. The data is still evolving, but after 15 months, 42% of adult lymphoma patients who received CD19 CAR T-cell therapy were still in remission. And two-thirds of childhood acute lymphoblastic leukemia patients were still in remission after six months. These are patients whose cancers were deemed very aggressive and for whom other standards of care had failed. CAR T cells and TCR T cells are engineered to produce special receptors on their surfaces. They are then expanded in the laboratory and returned to the patient. Credit: National Cancer Institute SHARE THIS PAGE: [...] Clinical trials in blood cancers have shown that even in patients whose cancer came back after multiple treatments, CAR T-cell therapy helped them achieve remissions that lasted for years. Others can live longer without their cancer getting worse, and in some cases can then benefit from curative cancer treatment such as stem cell transplantation.

• CAR T-Cell Therapy: What It Is & How It Works - Cleveland Clinic

  Yes, there are. Right now, there are six CAR T-cell therapies with U.S. Food and Drug Administration (FDA) approval to treat specific kinds of blood cancer. Those therapies are: Tisagenlecleucel (Kymriah®) to treat acute lymphoblastic leukemia in children and young adults. Brexucabtagene autoleucel (Tecartus®) to treat mantle cell lymphoma. Axicabtagene ciloleucel (Yescarta®) to treat several types of B-cell lymphomas. Lisocabtagene maraleucel (Breyanzi®), to treat diffuse large B-cell lymphoma. Idecabtagene vicleucel (Abecma®) and ciltacabtagene autoleucel (Carviykti®) to treat multiple myeloma. ## Treatment Details ### What happens before I have CAR T-cell therapy? [...] #### What conditions can CAR T-cell therapy treat? Right now, CAR T-cell therapy is an option to treat some blood cancers when other treatments aren’t effective or the condition comes back. Those blood cancer types include: B-cell acute lymphoblastic leukemia (ALL). Diffuse large B-cell lymphoma. Follicular lymphoma. High-grade B-cell lymphoma. Mantle cell lymphoma Multiple myeloma. Primary mediastinal large B-cell lymphoma. #### How does CAR T-cell therapy work? To understand how CAR T-cell therapy works, it may help to know more about T cells, which are white blood cells in your immune system. Your immune system monitors your body for intruders, including cancer, by tracking proteins called antigens on the surface of intruder cells. [...] Depending on your situation, you may have chemotherapy or radiation therapy after leukapheresis but before you receive CAR T cells. Your healthcare provider may call this bridging therapy. These treatments manage blood cancer during the time it takes to produce and grow enough CAR T cells to treat your condition. When it’s time for you to receive your new cells, you’ll undergo lymphodepleting chemotherapy. This treatment keeps your body from rejecting the CAR T cells. ### What happens during CAR T-cell therapy? The actual treatment involves receiving CAR T cells via infusion. CAR T-cell infusion takes between five and 30 minutes and is done via an intravenous line (IV). You may need to stay in the hospital during the procedure. The infusion process is like a blood transfusion:

• What is CAR-T Cell Therapy? - Kymriah

  Unlike traditional chemotherapy or allogenic stem cell transplant, CAR-T is a type of immunotherapy, called CAR-T cell therapy or chimeric antigen receptor T cell therapy. CAR-T is made up of your own T cells that have been reprogrammed to better detect and destroy cancerous (and normal) B cells in the body. # “One of the benefits of CAR-T cell therapy is that you only need one infusion of the engineered T cells. This means the potential of no more multiple intravenous infusions or daily oral medications.” # - Trish, an actual patient, who was compensated for her time. ## About KYMRIAH Learn more about KYMRIAH CAR-T cell therapy. Learn more ## Important Safety Information What is the most important information I should know about KYMRIAH? [...] ##### How does CAR-T cell therapy work? CAR-T cell therapy involves genetically modifying your T cells in the laboratory. The CAR gene, which codes for a receptor that helps T cells attach to a specific cell antigen, is added to the T cells. The CAR-T cells are then infused back into your body to target the cancer cells. ##### What should I expect with the CAR-T cell therapy process?

• CAR T-Cell Therapy | Fox Chase Cancer Center - Philadelphia PA

  The entire treatment typically takes up to a few weeks. CAR T cells usually reach peak levels about one to two weeks after infusion, and most patients will remain hospitalized for at least a week. Increasingly, however, patients are receiving CAR T therapy entirely in the outpatient setting. The most common side effect of CAR T-cell therapy is cytokine release syndrome, which indicates the body is mounting an immune response and presents similarly to a severe flu. [...] CAR T-cell therapy has proved to be a successful treatment option for certain leukemias and lymphomas in many patients who have shown resistance to chemotherapy and have either failed a transplant or aren’t considered a transplant candidate. Clinical trials at Fox Chase and around the world continue to evaluate CAR T-cell therapy in many other types of cancer as well. ## What To Do Next You can request an appointment online or call 888-369-2427. For general information or to ask us a question, please visit our Contact Us page. ## Related Articles 00 / 00 ### Home-Based Monitoring Could Transform Care for Patients Receiving T-Cell Redirecting Therapies Read More ### A Routine Blood Test Could Help Predict Who Benefits Most From CAR T-Cell Therapy [...] ## The CAR T-Cell Therapy Process To manufacture CAR T cells, blood is drawn from the patient and T cells are extracted. The T cells are sent to a specialized laboratory where scientists genetically modify them by adding a special receptor (CAR) that guides the T cells to find and eliminate cancer cells. The newly altered T cells are then multiplied by the millions in the lab and sent back to the hospital. As this process is occurring, patients receive a short course of low-dose chemotherapy before the modified T cells are infused back into the bloodstream, where they bind to the residual cancer cells and destroy them.